Hrs-2329
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Advanced Solid Tumors Harboring RAS Mutations or Amplifications cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hrs-7172 Tablets Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →